Markforged ships 100th metal 3D printing system
Additive manufacturing leader continues mission to transform the $12T manufacturing industry
WATERTOWN, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Markforged, the Boston-area 3D printer company transforming manufacturing, today announced it had shipped, globally, over 100 metal 3D printing systems. The company expects to more than double that number by the end of 2018, further establishing Markforged as the leader in affordable metal 3D printing. To learn more about the Metal X, please visit http://markforged.com/metal-x
The keys to unlocking massive adoption of additive manufacturing (AM) are cost and material selection. Markforged offers machines at a fraction of the price of both traditional manufacturing and existing metal 3D printers, and early customers are already saving hundreds of thousands of dollars per part. Shipping only since March, the company’s shipments now represent almost 10% of a 20 year old market. With the Metal X, Markforged is now enabling large scale manufacturers to 3D print functional prototypes, tools and fixtures, injection molds, and even end-use parts – all in metal, a material they already use every day.
With low cost and quick installation, the powerful and safe-to-operate Metal X system is enabling engineers and manufacturing professionals to address their business needs:
- Accelerate time to market for new innovative hardware by rapidly decreasing iteration cycles of traditional product development.
- Reduce the need for carrying low-turn inventory by printing aftermarket parts on-demand.
- Simplify logistics and reduce shipping costs by sending part designs directly to printers, whether they’re next door or across the world.
- Adjust production seamlessly, dynamically, and according to demand, simply switching from part to part in the same platform.
The proliferation of Markforged printers is even creating new manufacturing business models. Re3DTech is a Chicago-area 3D printing service bureau founded in 2016. Founders Russell Beck and Jim Teuber believed in the massive potential of 3D printing, and set up a facility to print parts for interested manufacturers. Thanks to Markforged metal (and composite) printers, their shop now serves hundreds of customers, from global manufacturers to local small business.
“Markforged – especially the Metal X – accelerated our ability to serve a higher level of the industry,” said Beck. “We’re educating more and more companies everyday on the power of additive. Customers can see the performance of the machines in an actual manufacturing environment and it’s incredible to watch them hold a Markforged-printed part for the first time. With Markforged, we nearly always exceed their expectations, and we don’t need hazmat suits or a million-dollar machine to do it.”
“Demand for affordable, strong, and safe metal 3D printing has never been greater,” said Greg Mark, CEO and founder of Markforged. “Markforged is drastically reducing the barriers to entry and opening up additive to more and more businesses every day. We can’t wait to see what 2019 has in store.”
Markforged transforms manufacturing with the most affordable 3D printers capable of producing parts tough enough for the factory floor. Engineers, designers, and manufacturing professionals all over the world rely on Markforged metal and composite printers for tooling, fixtures, functional prototyping, and high-value end-use production. Founded in 2013 and based in Watertown, MA, Markforged has over 200 employees globally, with $57 million in both strategic and venture capital. Markforged was recently selected by Forbes as one of the Next Billion Dollar startups. To learn more about Markforged, please visit https://markforged.com.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8de474ba-9270-48d9-b360-06f24ff13145.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CET | Pressemelding
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CET | Pressemelding
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera
Mattson Technology Announces Hydrilis™, a Unique High-Productivity Vacuum Wafer Process Platform18.3.2019 17:00:00 CET | Pressemelding
– Up to 4 process chambers and 8 wafer processing stations – – Smallest footprint, highest throughput platform – – Enables any process chamber, any position configuration flexibility – FREMONT, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Mattson Technology, Inc., a leading supplier of advanced process equipment used to manufacture semiconductors, introduces Hydrilis™, the industry’s highest productivity density vacuum transfer platform featuring high throughput on the smallest footprint. The Hydrilis platform can be configured with up to 4 process chambers, or 8 processing stations, for parallel or sequential wafer processing. Any of the paradigmE® family plasma etch process chambers, Suprema® family plasma photoresist strip and hard-mask removal process chambers, Novyka™ family surface treatment process chambers and Novyka family selective chemical dry etch process chambers can all be integrated on the Hydrilis platform. “Throughput per unit area of fab space is one of the key criteria
Minerva Neurosciences to Host Webcast Event on Schizophrenia18.3.2019 13:30:00 CET | Pressemelding
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader. Discussions will feature the following speakers
Infovista Enhances Ipanema SD-WAN with Nextgen Application Intelligence+ and Cloud-Native Orchestration18.3.2019 13:00:00 CET | Pressemelding
PARIS and ASHBURN, Va., March 18, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new cloud-native management and control with next-generation Application Intelligence+ for Ipanema SD-WAN, delivering unmatched application performance across any WAN. Tweet This: Infovista enhances Ipanema SD-WAN with nextgen Application Intelligence+ and cloud native orchestration: https://bit.ly/2ULcKLW #SmarterSDWAN The enterprise network has become the central nervous system of modern digital businesses, and SD-WAN is enabling this digital transformation. Infovista’s Ipanema SD-WAN with new cloud-native management and control of applications tightly combines session-based routing and dynamic path selection of the underlay network with an overlay of deep application visibility and dynamic control of the quality of experience for business-critical applications. Additionally, Ipanema automatically understands application delivery requirements and maintains a
Inspirata and Ohio State University Continue to Break Digital Pathology Barriers18.3.2019 12:30:00 CET | Pressemelding
Columbus, Ohio Columbus, Ohio, March 18, 2019 (GLOBE NEWSWIRE) -- Less than one year ago Inspirata announced that their digital pathology solution was used to make the first-ever primary digital diagnosis in the U.S., initiating a new era in cancer diagnostics. Today, cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced the company with the help of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) has broken another barrier- Inspirata and the OSUCCC – James have scanned over one-million anatomic pathology slides into high resolution whole slide digital images. “This historic accomplishment has demonstrated that it is possible to create large repositories of diagnostic quality prospective and retrospective slides creating imaging data that will accelerate clinical and research efforts,” says Inspirata Scan Center Manager, Trina Shanks, MLT (ACSP), CPC. Inspirata will presen